

# Maria Cristina Januário Santos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/192321/publications.pdf>

Version: 2024-02-01

46  
papers

1,305  
citations

430754

18  
h-index

360920

35  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2110  
citing authors

#	ARTICLE	IF	CITATIONS
1	Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. <i>Brain</i> , 2005, 128, 2260-2271.	3.7	114
2	G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. <i>Movement Disorders</i> , 2005, 20, 1653-1655.	2.2	106
3	Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. <i>Mitochondrion</i> , 2008, 8, 219-228.	1.6	102
4	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. <i>Neurobiology of Aging</i> , 2009, 30, 1515-1517.	1.5	97
5	The Impact of Mitochondrial Fusion and Fission Modulation in Sporadic Parkinson's Disease. <i>Molecular Neurobiology</i> , 2015, 52, 573-586.	1.9	79
6	Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment. <i>Scientific Reports</i> , 2016, 6, 28220.	1.6	68
7	Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls. <i>PLoS ONE</i> , 2019, 14, e0218826.	1.1	54
8	Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 599-603.	1.0	53
9	Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. <i>Experimental Neurology</i> , 2010, 222, 243-255.	2.0	53
10	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. <i>BMC Neurology</i> , 2008, 8, 1.	0.8	52
11	Bioenergetic dysfunction in Huntington's disease human cybrids. <i>Experimental Neurology</i> , 2011, 231, 127-134.	2.0	52
12	Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers. <i>Mitochondrion</i> , 2013, 13, 801-809.	1.6	39
13	Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?. <i>Experimental Neurology</i> , 2012, 238, 89-99.	2.0	37
14	The role of the basal ganglia in implicit contextual learning: A study of Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 1269-1273.	0.7	36
15	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	32
16	Motion integration deficits are independent of magnocellular impairment in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 314-320.	0.7	28
17	The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm. <i>Molecular Neurobiology</i> , 2015, 52, 1804-1820.	1.9	25
18	Tau and neurofilament light chain as fluid biomarkers in spinocerebellar ataxia type 3. <i>European Journal of Neurology</i> , 2022, 29, 2439-2452.	1.7	25

#	ARTICLE	IF	CITATIONS
19	Specific retinotopically based magnocellular impairment in a patient with medial visual dorsal stream damage. <i>Neuropsychologia</i> , 2006, 44, 238-253.	0.7	22
20	Clinical Features of Machado-Joseph Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1049, 255-273.	0.8	21
21	Specific impairment of visual spatial covert attention mechanisms in Parkinson's disease. <i>Neuropsychologia</i> , 2011, 49, 34-42.	0.7	18
22	Scanning Patterns of Faces do not Explain Impaired Emotion Recognition in Huntington Disease: Evidence for a High Level Mechanism. <i>Frontiers in Psychology</i> , 2012, 3, 31.	1.1	18
23	Parametric fMRI of paced motor responses uncovers novel whole-brain imaging biomarkers in spinocerebellar ataxia type 3. <i>Human Brain Mapping</i> , 2016, 37, 3656-3668.	1.9	16
24	Tremor Frequency Assessment by iPhone® Applications: Correlation with EMG Analysis. <i>Journal of Parkinson's Disease</i> , 2016, 6, 717-721.	1.5	15
25	Automatic classification of idiopathic Parkinson's disease and atypical Parkinsonian syndromes combining [ <sup>11</sup> C]raclopride PET uptake and MRI grey matter morphometry. <i>Journal of Neural Engineering</i> , 2021, 18, 046037.	1.8	15
26	Classification of Huntington's disease stage with support vector machines: A study on oculomotor performance. <i>Behavior Research Methods</i> , 2016, 48, 1667-1677.	2.3	14
27	Implicit Contextual Learning in Prodromal and Early Stage Huntington's Disease Patients. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 689-696.	1.2	13
28	A Novel Ecological Approach Reveals Early Executive Function Impairments in Huntington's Disease. <i>Frontiers in Psychology</i> , 2019, 10, 585.	1.1	12
29	Reliability and Validity of 39-Item Parkinson's Disease Questionnaire and Parkinson's Disease Quality of Life Questionnaire. <i>Acta Medica Portuguesa</i> , 2017, 30, 395-401.	0.2	11
30	Substantia nigra hyperechogenicity does not correlate with motor features in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 364, 9-11.	0.3	9
31	Transcranial Sonography and DaTSCAN in Early Stage Parkinson's Disease and Essential Tremor. <i>European Neurology</i> , 2016, 76, 252-255.	0.6	8
32	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. <i>PLoS ONE</i> , 2019, 14, e0210880.	1.1	8
33	The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 246.	1.2	7
34	A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	7
35	The concept of meaning: The key to clarify the human cognition and psychopathology. <i>Medical Hypotheses</i> , 2015, 84, 268-272.	0.8	5
36	Visual and ocular motor function in the atypical form of neurodegeneration with brain iron accumulation type I. <i>British Journal of Ophthalmology</i> , 2018, 102, 102-108.	2.1	5

#	ARTICLE	IF	CITATIONS
37	Cognition, function and awareness of disease impact in early Parkinson's and Huntington's disease. <i>Disability and Rehabilitation</i> , 2022, 44, 920-938.	0.9	5
38	Posterior reversible encephalopathy syndrome: the importance of early diagnosis. <i>BMJ Case Reports</i> , 2012, 2012, bcr2012006852-bcr2012006852.	0.2	4
39	Pinball-intrusions in spinocerebellar ataxia type 3. <i>Neurology</i> , 2018, 90, 36-37.	1.5	4
40	Hereditary spastic paraparesis: The real-world experience from a Neurogenetics outpatient clinic. <i>European Journal of Medical Genetics</i> , 2022, 65, 104430.	0.7	4
41	Parkinson's Disease and Mitochondrial DNA NADH Dehydrogenase Subunit 1 Nucleotides 3337-3340: Study in a Population from the Central Region of Portugal (Coimbra). <i>European Neurology</i> , 2003, 50, 60-61.	0.6	3
42	Parkinson's disease with hypocalcaemia: adult presentation of 22q11.2 deletion syndrome. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223751.	0.2	3
43	Tremor modulations across periods with and without voluntary motion and limb load task demands using movement quantification. , 2013, 2013, 4338-41.		2
44	Classification of Huntington's Disease Stage with Features Derived from Structural and Diffusion-Weighted Imaging. <i>Journal of Personalized Medicine</i> , 2022, 12, 704.	1.1	2
45	Protocol for the Characterization of the Cytosine-Adenine-Guanine Tract and Flanking Polymorphisms in Machado-Joseph Disease. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 782-793.	1.2	1
46	Cognition and meaning. <i>Medical Hypotheses</i> , 2016, 94, 57.	0.8	0